Ascensia launches Eversense E3 in US
By HME News Staff
Updated 9:54 AM CDT, Tue April 5, 2022
PARSIPPANY, N.J. – Ascensia Diabetes Care has launched the next-generation Eversense E3 Continuous Glucose Monitoring System for patients in the U.S., alongside the new Eversense PASS savings program. Eversense E3, which is developed be Senseonics Holdings, was approved for use up to six months by the U.S. Food and Drug Administration earlier this year, making it the longest lasting CGM sensor available in the country. “We are thrilled to offer Eversense E3 to people with diabetes in the U.S. and are proud to do this alongside a favorable Payment Assistance and Savings Program,” said Robert Schumm, president at Ascensia. “Eversense E3’s offering is truly differentiated and we believe it is important to make the system as affordable as possible. We have been working closely with payers on coverage and our dedicated CGM commercial team is eager to introduce the product to more patients, so they can experience the unique benefits of the Eversense system.” Under the Eversense PASS program, users pay only $99 out of pocket for their first sensor and smart transmitter. After that, users pay no more than $100 per month or $600 for the duration of each sensor.
Comments